Hexa Reports

Market Research Reports and Insightful Company Profiles

CNV-2197944 Industry 2015,Share and Size,Trends and

Price,Forecast and Market Analysis to 2022

Summary
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different
from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference
between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in
neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain
syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic
neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat
these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical
treatments. However, despite the availability of multiple pain medications only 50% of patients respond
to any given drug and there are numerous the side effects associated particularly with systemically
administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in
terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably
eradicated NP in targeted patient populations, as well as offering an improved safety profile.
CNV-2197944 is a novel therapy being developed by Convergence Pharmaceuticals for the treatment of
chronic pain. It is currently in Phase II of clinical development for both PHN and PDN. The drug was
acquired from GlaxoSmithKline (GSK) in 2010 as part of an agreement in which GSK acquired an 18%
minority equity stake in Convergence Pharmaceuticals. However, as part of the restructuring of

Hexa Reports
Market Research Reports and Insightful Company Profiles
Convergence in 2011, CNV-2197944 was transferred to Calchan Ltd., a sister company of Convergence
Pharmaceuticals, which now holds the proprietary rights to CNV-2197944.
Browse Detail Report With TOC @ http://www.hexareports.com/report/cnv-2197944-neuropathicpain-forecast-and-market-analysis-to-2022/details
Scope

Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis,

pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on CNV-2197944 including product description, safety and efficacy profiles
as well as a SWOT analysis.
Sales forecast for CNV-2197944 for the top six countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Request a sample copy of this Report @ http://www.hexareports.com/sample/41964

Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for
Neuropathic pain
Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
Make more informed business decisions from insightful and in-depth analysis of CNV-2197944
performance
Obtain sales forecast for CNV-2197944 from 2012-2022 in the top six countries (the US, France,
Germany, Italy, Spain and the UK).
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 14
3.1.1 Painful Diabetic Neuropathy 16
3.1.2 Postherpetic Neuralgia 17
3.1.3 Trigeminal Neuralgia 17

Hexa Reports
Market Research Reports and Insightful Company Profiles
3.2 Etiology and Pathophysiology 18
3.2.1 Etiology 19
3.2.2 Pathophysiology 20
4 Disease Management 28
4.1 Diagnosis and Treatment Overview 28
4.1.1 Diagnosis 28
4.1.2 Treatment Overview and Guidelines 35
Browse Full Report @ http://www.hexareports.com/report/cnv-2197944-neuropathic-pain-forecastand-market-analysis-to-2022/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.

Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/